Osteosarcoma treatment market

Oct 30, 2026

Summary Osteosarcoma treatment remains chemotherapy-dominated, with standard care combining surgery, chemotherapy, and, in selected cases, radiation therapy. The market continues to face significant unmet medical needs, with few treatments specifically approved for osteosarcoma. KHAPZORY is FDA-approved in t...

Oct 19, 2026

Summary Osteosarcoma is a rare, aggressive primary bone cancer that primarily affects adolescents and young adults. The total incident population across the seven major markets reached approximately 2,200 cases in 2025.  In the United States, Acrotech Biopharma’s Levoleucovorin (KHAPZORY) has received FDA ap...

Oct 30, 2023

Bone sarcoma is a rare and aggressive form of cancer that develops in bone tissue. The likelihood of a person being diagnosed with primary bone sarcoma and their recovery prospects depend on various unique factors. In 2023, it is expected that 4,000 individuals across all age groups in the United States will receiv...

Feb 28, 2022

Osteosarcoma and Ewing sarcoma are two of the most common malignancies of bone tissues present in children. Osteosarcoma treatment usually involves surgery and chemotherapy and Ewing sarcoma treatment typically begins with chemotherapy only. Dr. James Ewing who described the tumor in the 1920’s distinguished the tu...

Oct 05, 2020

The current treatment approach for high-grade Osteosarcoma is conventional surgical resection of the primary tumor, along with systemic chemotherapies and radiation therapies in case of metastases and recurrence. Despite the rarity of Osteosarcoma, cancer poses a major global health burden with a global incidence r...

Oct 02, 2020

Osteosarcomas are rare, yet are the leading cause of deaths due to cancer in the pediatric population. It is a high-grade malignancy of mesenchymal origins. They are the most frequent forms of primary bone tumors and account for approximately 20% of all the bone tumors. With the incident population of less than 250...